Provided By GlobeNewswire
Last update: Dec 9, 2024
- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition
Read more at globenewswire.comNASDAQ:MGTX (7/24/2025, 11:24:33 AM)
8.38
-0.11 (-1.3%)
Find more stocks in the Stock Screener